pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 45 | Non-oncology: 30 Oncology: 15 |
| Under Consideration for Negotiation | 12 | Non-oncology: 5 Oncology: 7 |
| Completed Negotiations | 819 | With Letter of Intent: 711 Without agreement: 108 |
| Negotiations That Were Not Pursued | 110 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Jemperli | GlaxoSmithKline Inc. | In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. | |
| Casgevy | Vertex Pharmaceuticals (Canada) Incorporated | Transfusion-dependent β-thalassemia | |
| Abilify Asimtufii | Otsuka Canada Pharmaceutical Inc. | Schizophrenia | |
| Casgevy | Vertex Pharmaceuticals (Canada) Incorporated | Sickle cell disease | |
| Noyada | Ethypharm Inc. | Multiple Indications | |
| Lumakras | Amgen Canada Inc. | Advanced non-small cell lung cancer, KRAS G12C-mutated | |
| Yesintek | Biocon Biologics Canada Inc. | Multiple Indications | |
| Otulfi | Fresenius Kabi Canada Ltd. | Multiple Indications | |
| Darzalex SC | Janssen Inc. | in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. |